Surrozen Reports Massive $242M Net Loss for 2025 Amidst Pipeline Updates and $5M Milestone
SRZN has more than doubled off its 52-week low of $5.9.
Summary
Surrozen, Inc. reported a substantial net loss of $242.0 million for the full year 2025, significantly higher than the previous year, alongside a $5 million milestone payment from Boehringer Ingelheim and progress on its lead drug candidates.
Key Events · Earnings and Guidance · SRZN
-
Significant Net Loss Reported
The company reported a net loss of $242.0 million, or ($32.37) per share, for the full year 2025, a substantial increase from $63.6 million in 2024.
-
Boehringer Ingelheim Milestone Payment
Surrozen received a $5.0 million milestone payment from Boehringer Ingelheim for SZN-413, following positive IND-enabling toxicology study results.
-
Pipeline Advancement on Track
The company remains on track to submit an Investigational New Drug (IND) application for its lead candidate, SZN-8141, in the second half of 2026.
-
Cash Position and Recent Financing
Cash and cash equivalents stood at $89.2 million as of December 31, 2025, supplemented by $26.9 million from at-the-market sales in January 2026 and $3.3 million from warrant exercises in February and March 2026.
Analysis · SRZN · Life Sciences
The reported net loss of $242.0 million for 2025 is extremely large, exceeding the company's current market capitalization, and reflects significant non-cash losses related to a 2025 PIPE and warrant liabilities. While the company secured a $5 million milestone payment and is advancing its SZN-8141 IND application for H2 2026, the dramatic increase in net loss from $63.6 million in 2024 highlights severe financial challenges. Investors should scrutinize the company's cash burn and future financing needs, despite the recent ATM sales and warrant exercises providing some near-term liquidity.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRZN was trading at $25.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $216.3M. The 52-week trading range was $5.90 to $29.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.